Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
2.
Biosens Bioelectron ; 213: 114449, 2022 Oct 01.
Article in English | MEDLINE | ID: covidwho-1944326

ABSTRACT

Currently, vaccination is the most effective medical measure to improve group immunity and prevent the rapid spread of COVID-19. Since the individual difference of vaccine effectiveness is inevitable, it is necessary to evaluate the vaccine effectiveness of every vaccinated person to ensure the appearance of herd immunity. Here, we developed an artificial intelligent (AI)-assisted colorimetric polydopamine nanoparticle (PDA)-based lateral flow immunoassay (LFIA) platform for the sensitive and accurate quantification of neutralizing antibodies produced from vaccinations. The platform integrates PDA-based LFIA and a smartphone-based reader to test the neutralizing antibodies in serum, where an AI algorithm is also developed to accurately and quantitatively analyze the results. The developed platform achieved a quantitative detection with 160 ng/mL of detection limit and 625-10000 ng/mL of detection range. Moreover, it also successfully detected totally 50 clinical serum samples, revealing a great consistency with the commercial ELISA kit. Comparing with commercial gold nanoparticle-based LFIA, our PDA-based LFIA platform showed more accurate quantification ability for the clinical serum. Therefore, we envision that the AI-assisted PDA-based LFIA platform with sensitive and accurate quantification ability is of great significance for large-scale evaluation of vaccine effectiveness and other point-of-care immunoassays.


Subject(s)
Biosensing Techniques , COVID-19 , Metal Nanoparticles , Antibodies, Neutralizing , Artificial Intelligence , COVID-19/diagnosis , Colorimetry , Gold , Humans , Immunoassay/methods , Limit of Detection
3.
Journal of the Formosan Medical Association = Taiwan yi zhi ; 2022.
Article in English | EuropePMC | ID: covidwho-1615420
4.
STAR Protoc ; 2(3): 100793, 2021 09 17.
Article in English | MEDLINE | ID: covidwho-1368796

ABSTRACT

This protocol describes an in vitro fluorogenic assay to measure the proteolytic activity and identify inhibitors of Mpro, the main protease produced by SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2). Studies to identify potential inhibitors of Mpro mainly rely on in silico molecular dynamics simulations or on FRET (Fluorescence Resonance Energy Transfer) substrates. The protocol is based on an aminomethyl coumarin substrate. High sensitivity, specificity, and an easily detectable fluorescent read-out are the advantages offered by this rapid assay, which allows high throughput screening of new Mpro inhibitors.


Subject(s)
Antiviral Agents/pharmacology , COVID-19 Drug Treatment , Coronavirus 3C Proteases/antagonists & inhibitors , Fluorescence Resonance Energy Transfer/methods , Protease Inhibitors/pharmacology , SARS-CoV-2/enzymology , Viral Proteins/antagonists & inhibitors , COVID-19/metabolism , COVID-19/virology , Coronavirus 3C Proteases/metabolism , Coumarins/metabolism , Drug Discovery , High-Throughput Screening Assays , Humans , In Vitro Techniques
SELECTION OF CITATIONS
SEARCH DETAIL